PPT-Switch to INSTI + NNRTI

Switch to DTG RPV SWORD Study Switch to CAB LA RPV LA IM LATTE2 Study LATTE2 Study switch to cabotegravir LA rilpivirine LA IM Objective Primary HIV RNA lt 50 cmL at W32 of maintenance phase selection of dosing schedule for phase III studies confirmation of dose on W48 analysis safety. Planning and . Implementation. July 2015. 1. Contents. Polio Endgame Objective 2. Rationale for switching from tOPV to bOPV. Dates and timelines around the Switch. Guidance for implementation:. Plan. 2013. What do we use electricity for?. Where does electricity come from?. How can we save electricity at home and at school?. Save money for your family and . save your planet. Make the pledge and switch off. monotherapy. MONOI. MONET. PROTEA. DRV600. Design. Objective. Non inferiority in the proportion of patients with HIV-1 RNA < 50 c/. mL. at W48 (ITT analysis, missing/discontinuation/switch= failure, snapshot algorithm. M Harris, . S Guillemi. , K Chan, B Yip. ,. . M Hull, V Dias Lima, R Hogg, J . Montaner. Abstract #: WEAB0202. Organ Dysfunction in HIV: It's . Complicated. Wednesday, 3 July 2013 14:30-16:. 00. Session . QDMRK. SPRING-2. ONCEMRK. ONCEMRK. Design. Objective. Non inferiority of RAL QD: % HIV RNA < 40 c/mL by ITT, NC=F . (lower margin of the 2-sided 95% CI for the difference = - 10%, 90% power). RAL 1200 mg ** QD + . Bob Combs. Hyper-V Networking. Microsoft Corporation. VIR307. Agenda. What networking in the cloud means. So what’s new in the Hyper-V virtual switch. What is a Hyper-V Extensible Switch. Give me details!. Statements. switch . (expression) {. case . value1:. . statement(s);. . break. ;. case . value2:. statement(s);. break. ;. . ….. case . valueN. :. statement(s);. . break. ;. default: . a unified view of micro-architecture and circuits. Giorgos Dimitrakopoulos. Electrical and Computer Engineering. Democritus University of Thrace (DUTH). Xanthi, Greece. dimitrak@ee.duth.gr. http://utopia.duth.gr/~dimitrak. ENCORE. EFV vs RPV. ECHO-THRIVE. STAR. EFV vs ETR. SENSE. DOR vs EFV. DRIVE-AHEAD. Design. Objective. Non inferiority of EFV 400 mg at W48: % HIV RNA < 200 c/. mL. by modified intention to treat analysis (all randomised participants who received at least . disconnector. PPMV – Product Management. GSec. Three position . switch. . disconnector. Month DD, Year. | Slide . 2. © ABB Group. Upper terminal. Lower terminal. Capacitive . dividers. . intergrated. SWORD. . Study. Switch to CAB LA RPV LA IM. LATTE-2 Study. . . LATTE-2 Study: switch to cabotegravir LA rilpivirine LA IM. Objective. Primary: % HIV RNA < 50 c/mL at W32 of maintenance phase: selection of dosing schedule for phase III studies (confirmation of dose on W48 analysis) ; safety. ENCORE. EFV vs RPV. ECHO-THRIVE. STAR. EFV vs ETR. SENSE. DOR vs EFV. DRIVE-AHEAD. Design. Objectives. Non inferiority of DOR at W48: % HIV RNA < 50 c/mL by intention to treat, snapshot analysis (lower margin of the 95% CI for the difference = - 10%, . stop using your credit cards - switch to MOVO to spend just what you have budgeted for the month Dathan M. Byonanebye, Mark N. Polizzotto, Fernando Maltez, Andri Rauch, Katharina Grabmeier-Pfistershammer, Ferdinand Wit, Stéphane De Wit, Antonella Castagna, Antonella . D’Arminio. Monforte, Cristina Mussini, Jan-Christian Wasmuth, Eric .